Literature DB >> 23486270

Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.

Denis Maillet1, Isabelle Martel-Lafay, Dominique Arpin, Maurice Pérol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23486270     DOI： 10.1097/JTO.0b013e318288dc2d

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  17 in total

Review 1.  Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Authors:  Priscilla K Brastianos; Franziska Maria Ippen; Umbreen Hafeez; Hui K Gan
Journal:  Oncologist       Date:  2018-04-27

2.  PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Authors:  Helen Y Zou; Luc Friboulet; David P Kodack; Lars D Engstrom; Qiuhua Li; Melissa West; Ruth W Tang; Hui Wang; Konstantinos Tsaparikos; Jinwei Wang; Sergei Timofeevski; Ryohei Katayama; Dac M Dinh; Hieu Lam; Justine L Lam; Shinji Yamazaki; Wenyue Hu; Bhushankumar Patel; Divya Bezwada; Rosa L Frias; Eugene Lifshits; Sidra Mahmood; Justin F Gainor; Timothy Affolter; Patrick B Lappin; Hovhannes Gukasyan; Nathan Lee; Shibing Deng; Rakesh K Jain; Ted W Johnson; Alice T Shaw; Valeria R Fantin; Tod Smeal
Journal:  Cancer Cell       Date:  2015-07-02       Impact factor: 31.743

3.  Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.

Authors:  Hitomi Ajimizu; Young Hak Kim; Michiaki Mishima
Journal:  Med Oncol       Date:  2015-01-03       Impact factor: 3.064

Review 4.  ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

Authors:  Mark M Awad; Alice T Shaw
Journal:  Clin Adv Hematol Oncol       Date:  2014-07

5.  Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Authors:  Yuan-Yuan Lei; Jin-Ji Yang; Wen-Zhao Zhong; Hua-Jun Chen; Hong-Hong Yan; Jie-Fei Han; Lu-Lu Yang; Yi-Long Wu
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

Review 6.  Systemic therapy of brain metastases.

Authors:  Harry C Brastianos; Daniel P Cahill; Priscilla K Brastianos
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

Review 7.  Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

Review 8.  Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.

Authors:  Rimas V Lukas; Maciej S Lesniak; Ravi Salgia
Journal:  CNS Oncol       Date:  2014-01

9.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Authors:  Priscilla K Brastianos; Scott L Carter; Gad Getz; William C Hahn; Sandro Santagata; Daniel P Cahill; Amaro Taylor-Weiner; Robert T Jones; Eliezer M Van Allen; Michael S Lawrence; Peleg M Horowitz; Kristian Cibulskis; Keith L Ligon; Josep Tabernero; Joan Seoane; Elena Martinez-Saez; William T Curry; Ian F Dunn; Sun Ha Paek; Sung-Hye Park; Aaron McKenna; Aaron Chevalier; Mara Rosenberg; Frederick G Barker; Corey M Gill; Paul Van Hummelen; Aaron R Thorner; Bruce E Johnson; Mai P Hoang; Toni K Choueiri; Sabina Signoretti; Carrie Sougnez; Michael S Rabin; Nancy U Lin; Eric P Winer; Anat Stemmer-Rachamimov; Matthew Meyerson; Levi Garraway; Stacey Gabriel; Eric S Lander; Rameen Beroukhim; Tracy T Batchelor; Jose Baselga; David N Louis
Journal:  Cancer Discov       Date:  2015-09-26       Impact factor: 39.397

Review 10.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.